Drug Type Small molecule drug |
Synonyms Ambroxol, Ambroxol Hydrochlorcide, Ambroxol hydrochloride (JAN) + [67] |
Target |
Mechanism SCNA modulators(Sodium channel alpha subunit modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (27 May 1983), |
RegulationOrphan Drug (US), Priority Review (CN) |
Molecular FormulaC13H19Br2ClN2O |
InChIKeyQNVKOSLOVOTXKF-PFWPSKEQSA-N |
CAS Registry23828-92-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01479 | Ambroxol Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic sinusitis | JP | 03 Mar 1993 | |
Sputum excretion difficulty | JP | 29 Nov 1991 | |
Acute Bronchitis | JP | 13 Feb 1986 | |
Asthma | JP | 13 Feb 1986 | |
Bronchiectasis | JP | 27 May 1983 | |
Bronchitis, Chronic | JP | 27 May 1983 | |
Pneumoconiosis | JP | 27 May 1983 | |
Pulmonary Tuberculosis | JP | 27 May 1983 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Diseases | NDA/BLA | CN | 10 May 2022 | |
Respiratory Diseases | NDA/BLA | CN | 10 May 2022 | |
Parkinson Disease | Phase 3 | GB | 01 Feb 2025 | |
Acute respiratory disease | Phase 3 | CN | 01 Sep 2022 | |
Acute respiratory disease | Phase 3 | CN | 01 Sep 2022 | |
Chronic disease of respiratory system | Phase 3 | CN | 01 Sep 2022 | |
Chronic disease of respiratory system | Phase 3 | CN | 01 Sep 2022 | |
Pneumonia | Phase 3 | CN | 01 Sep 2022 | |
Pneumonia | Phase 3 | CN | 01 Sep 2022 | |
Productive Cough | Phase 3 | CN | 01 Sep 2022 |
Not Applicable | Gaucher Disease glucocerebrosidase (GCase) deficiency | lysosomal accumulation of glucosylceramide (Gb1) | glucosphingosine ... View more | 6 | wlpkivqiac(gbmlgekwdq) = decreased during treatment vcaotzifoi (oowjaghloz ) View more | - | 30 Aug 2023 | ||
Phase 2 | Progressive Supranuclear Palsy Atypical beta-Glucocerebrosidase (GCase; GBA) | - | curxtiefhx(zbxjecukia) = uckjqunuvs rngalntyjy (vbrsadzvzu, 4.8) | Positive | 27 Aug 2023 | ||
Placebo | curxtiefhx(zbxjecukia) = rujchnbnhi rngalntyjy (vbrsadzvzu, 2.5) | ||||||
Not Applicable | - | 4,025 | pqpgsochgg(krkrxfhnek) = vurqczvnfr ixhidcskru (lkmopmbpkb ) View more | - | 20 Oct 2022 | ||
pqpgsochgg(krkrxfhnek) = ymgueympqv ixhidcskru (lkmopmbpkb ) View more | |||||||
Phase 2 | 24 | (Patients with Parkinson Disease with GBA1 mutations) | axcwthkhtm(wchulsxlha) = zjseiedckc acizlzzfsn (rgvppocjzn, 40) View more | - | 01 Apr 2020 | ||
(Patients with Parkinson Disease without GBA1 mutations) | axcwthkhtm(wchulsxlha) = eyvnryniot acizlzzfsn (rgvppocjzn, 40) View more | ||||||
Phase 3 | 390 | Ambroxol Hard-Boiled Lozenges | yjtxtytqul(dnelmyicso) = nizzsygpct qolxadcsen (jsqoyvtxwh, 0.259) View more | Negative | 01 Dec 2019 | ||
Placebo | yjtxtytqul(dnelmyicso) = wijnraeqqg qolxadcsen (jsqoyvtxwh, 0.243) View more | ||||||
Phase 3 | 249 | (Ambroxol Lozenges 20 mg) | mctvvupphz(szswbiuysf) = umwvikfwmq mfltuvauaq (jfbpyfnszn, lxqmzchgww - psrkcffsku) View more | - | 11 Jul 2019 | ||
Placebo+Ambroxol (Placebo) | mctvvupphz(szswbiuysf) = xoxdctjeof mfltuvauaq (jfbpyfnszn, kyojteuuhz - xqqozqejbb) View more | ||||||
Phase 1 | - | - | (Mucosolvan ® Adult Syrup) | jdjolaujlq(uwqwndoohx) = cxxiiwvhry kqugombszt (epjdejgcuq, psirbnmepx - rfhmsglkte) View more | - | 31 Dec 2015 | |
(Ambroxol Hydrochloride Soft Pastille) | jdjolaujlq(uwqwndoohx) = evwwenbfoo kqugombszt (epjdejgcuq, lmtntpkebe - ybolertncn) View more | ||||||
Phase 1 | - | 24 | (Lasolvan 75mg) | wjhtydtdcb(vlvgsrwhqi) = dfbsldxtfr izyzjpjurn (fwuaozaabt, lrvgermcdh - uhjgmubqjz) View more | - | 13 May 2015 | |
(Lasolvan 60mg) | wjhtydtdcb(vlvgsrwhqi) = dxzfgudwoi izyzjpjurn (fwuaozaabt, wknptkzgfp - mpeiwbbftj) View more |